Dr. Brandes is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
2315 GOLF CLUB LN
Nashville, TN 37215Phone+1 615-516-0711
Summary
- As the founder and director of Nashville Neuroscience Group, Jan Lewis Brandes, MD, MS, also holds an appointment as an Assistant Clinical Professor in the Department of Neurology at Vanderbilt University School of Medicine, Nashville, Tennessee. Prior to attending Vanderbilt University School of Medicine, where she subsequently earned her medical degree, Dr. Brandes attended the Robert Koch Institute of Virology, Free University in Berlin, Federal Republic of Germany, as a Fulbright Scholar. Her postgraduate medical training was completed at Vanderbilt University Medical Center where she served as chief resident in neurology. She also holds a Master of Science degree in microbiology from the University of Tennessee in Knoxville. She is certified by the National Board of Medical Examiners, The American Board of Psychiatry and Neurology and the National Board for Certification in Headache Management.
Dr. Brandes has been active in clinical trials for more than two decades. She has served as the principal or co-principal investigator in more than st100 studies, primarily examining issues in migraine including acute treatment, prophylaxis and menstrual migraine. She has published extensively in peer-reviewed journals including JAMA, Cephalalgia, Headache, and Mayo Clinic Proceedings.
Dr. Brandes is the immediate past chairman of Nashville Metro General Hospital Authority, a fellow of the American Headache Society and the American Academy of Neurology, and serves on the National Headache Foundation Board. She is a former member of the board of directors of the American Headache Society and is a past president of the American Council for Headache Education. In recognition of her professional endeavors, she has been named to Best Doctors in the Americas from 1996 to present.
Education & Training
- Vanderbilt University Medical CenterResidency, Neurology, 1990 - 1993
- Vanderbilt University Medical CenterInternship, Internal Medicine, 1989 - 1990
- Vanderbilt University School of MedicineClass of 1989
- Robert Koch Institute of VirologyFulbright Scholarship, Molecular Virology, 1982 - 1983
- University of TennesseeMS, Microbiology, subspecialty, herpes virology, 1977 - 1980
- Mississippi University for WomenBS, Biology, Cum Laude, 1975
Certifications & Licensure
- TN State Medical License 1991 - 2026
- American Board of Psychiatry and Neurology Neurology
- United Council for Neurologic SubspecialtiesCertification in Headache Medicine
Awards, Honors, & Recognition
- Lifetime Achievement Award National Headache Foundation, 2022
- Fulbright Scholar Robert Koch Institute of Virology
- Best Doctors in the Americas 1995-2018
- Join now to see all
Clinical Trials
- A Study on the Usability of the Needle-free Intraject® System in Adult Patients During Acute Migraine Attack Start of enrollment: 2007 Sep 01
Publications & Presentations
PubMed
- 361 citationsARISE: A Phase 3 randomized trial of erenumab for episodic migraine:David W. Dodick, Messoud Ashina, Jan Lewis Brandes, David Kudrow, Michel Lanteri-Minet
Cephalalgia. 2018-02-22 - 451 citationsSafety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trialStewart J. Tepper, Messoud Ashina, Uwe Reuter, Jan Lewis Brandes, David Doležil
The Lancet. Neurology. 2017-06-01 - 335 citationsEfficacy and safety of topiramate for the treatment of chronic migraine: a randomized, double-blind, placebo-controlled trial.Stephen D. Silberstein, Richard B. Lipton, David W. Dodick, Frederick G. Freitag, Nabih M. Ramadan
Headache. 2007-02-01
Journal Articles
- ARISE: A Phase 3 Randomised Trial of Erenumab for Episodic MigraineDodick, D, Ashina, M., Brandes, J, Kudrow, D, Lanteri-Minet, M, Osipova, V, Palmer K, Picard, H, Mikol, D, Lenz R, Lancet Neurology
- Safety and Efficacy of Erenumab for Preventive Treatment of Chronic Migraine: A Randomused, Double-Blind, Plecebo-Controlled Phase 2 TrialBrandes JL, Tepper S, Ashina M, Reuter U, Lenz R, The Lancet Neurology, 1/1/2017
- Sex Differences in the Study of Neurological IllnessesAttarian H, Brandes JL, Dafer R, Giesser B, Behavioral Neurology, 1/1/2015
- Join now to see all
Books/Book Chapters
Abstracts/Posters
- Multiple-Attack Efficacy and Tolerability of Sumavel DosePro (needle-free subcutaneous sumatriptan) Among Current Triptan UsersBrandes JL, Rothrock J, Cady R, Aurora S, Fox AW, Farr SJ, AAN Scientific Meeting, 1/1/2011
- Randomized, Controlled Trial of Telcagepant in Acute Treatment of Migraine in Patients with Stable Coronary Artery DiseaseHo TW, Ho AP, Chaitman BR, Johnson C, Mathew NT, Kost J, Fan X, Aurora S, Brandes JL, Fei K, Beebe L, Lines C, Krucoff M, Merck Research Laboratories, 1/1/2010
- Migrainous Vertigo Presenting in the PerimenopauseBrandes JL, Roberson S, Bennett M, Haynes D, 63nd Annual Meeting of the American Academy of Neurology, Toronto, 1/1/2010
- Join now to see all
Lectures
- The Neurological ExaminationVanderbilt University School of Medicine, Nashville, TN - 1/1/2017
- Vestibular Headache/ DysautonomiaLake Buena Vista, FL - 1/1/2016
- 25th Annual Practicing Physicians Approach to the Difficult Headache PatientDiamond Headache Clinic Reseach and Educational Foundation, Rancho Mirage, California
- Join now to see all
Other
- Infertile Women Significantly More Likely To Have MigrainesBrandes J, Pain Medicine News – Headache and Migraine
1/1/2005 - Headache Medication Interactions: Focus on the TriptansBrandes JL and Tepper S, CNS News Special Edition
1/1/2003 - Perspectives on Managed Care – Managing with Managed CareJan Lewis Brandes, M.D., HEADACHE – Newsletter of the American Council for Headache Education
1/1/1998 - Join now to see all
Press Mentions
- 5 of the Most Common Migraine TriggersJuly 13th, 2021
- Nashville General Hospital Seeks $20M Boost to Annual City SubsidyMarch 17th, 2017
- FDA Approves ReyvowOctober 13th, 2019
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: